Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9574173 | 0.98 | MAOB (0.43) | MAOBAPPEGFRMEN1LMNA | |
| Hydrochloric Acid SCHEMBL11671567 | 0.90 | APP (0.47) | MAOBAPPMEN1LMNAKMT2A | |
| SCHEMBL10477860 | 0.83 | KDM4E (0.41) | MAOBMEN1LMNAKMT2A | |
| SCHEMBL10077369 | 0.83 | CDK1 (0.42) | MAOBMEN1KMT2A | |
| SCHEMBL10592068 | 0.81 | MAOB (0.40) | MAOBAPPMEN1KMT2A | |
| SCHEMBL456296 | 0.80 | FOLH1 (0.43) | MAOBEGFR | |
| SCHEMBL9668333 | 0.79 | MAOB (0.42) | MAOBAPPMEN1KMT2A | |
| SCHEMBL11750936 | 0.78 | SMN1; SMN2 (0.47) | MAOBEGFRMEN1LMNAKMT2A | |
| SCHEMBL469526 | 0.77 | THRA (0.48) | — | |
| SCHEMBL10477760 | 0.77 | MEN1 (0.47) | MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012032546-A2 | PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110118358-A1 | DEUTERIUM-ENRICHED SALMETEROL | PROTIA, LLC (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118358-A1 | DEUTERIUM-ENRICHED SALMETEROL | PROTIA, LLC (US) | 2011-05-19 | — | — | US | disclosed |
| US-20080319086-A1 | DEUTERIUM-ENRICHED SALMETEROL | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080319086-A1 | DEUTERIUM-ENRICHED SALMETEROL | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157656-A1 | DEUTERIUM-ENRICHED SALMETEROL | PROTIA LLC (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319086-A1 | DEUTERIUM-ENRICHED SALMETEROL | HSD3B1, HSD3B2, HSD11B1 | MAOB 2313/4885APP 3580/4885EGFR 3345/4885 |
| US-20110118358-A1 | DEUTERIUM-ENRICHED SALMETEROL | HSD3B1, HSD3B2, HSD11B1 | MAOB 2313/4885APP 3580/4885EGFR 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.